Characteristics of human failing permeabilized myocytes before and after 3 h cTn exchange containing cTnI S23/24DD
| Human samples . | Myofibrillar preparations . | |
|---|---|---|
| Before . | After S2223DD . | |
| n | 6 | |
| Fiber length (µm) | 148 ± 10 | |
| Fiber width (µm) | 25 ± 3 | |
| Resting sarcomere length (µm) | 2.25 ± 0.02 | |
| Passive force (µN) | 0.52 ± 0.13 | 0.44 ± 0.16 |
| Passive tension (kN/m2) | 1.48 ± 0.21 | 0.96 ± 0.23 |
| Max force (µN) | 15.1 ± 4.6 | 12.6 ± 3.5a |
| Max tension (kN/m2) | 39.9 ± 3.4 | 34.9 ± 3.2a |
| ktr @ pCa 4.5 (s−1) | 0.712 ± 0.08 | 0.595 ± 0.06a |
| pCa for half-maximal force | 6.08 ± 0.03 | 5.88 ± 0.03a |
| Relative force (PO/P4.5) | 0.49 ± 0.04 | 0.55 ± 0.03 |
| a/PO | 0.16 ± 0.02 | 0.23 ± 0.05 |
| Fopt (P/PO) | 0.266 ± 0.01 | 0.291 ± 0.02 |
| Vopt (ML/s) | 0.104 ± 0.010 | 0.117 ± 0.013 |
| Vmax | 0.39 ± 0.04 | 0.42 ± 0.08 |
| PNPO (P/PO*ML/s) | 0.027 ± 0.002 | 0.033 ± 0.003a |
| Submax ktr | 0.552 ± 0.10 | 0.772 ± 0.11a |
| Human samples . | Myofibrillar preparations . | |
|---|---|---|
| Before . | After S2223DD . | |
| n | 6 | |
| Fiber length (µm) | 148 ± 10 | |
| Fiber width (µm) | 25 ± 3 | |
| Resting sarcomere length (µm) | 2.25 ± 0.02 | |
| Passive force (µN) | 0.52 ± 0.13 | 0.44 ± 0.16 |
| Passive tension (kN/m2) | 1.48 ± 0.21 | 0.96 ± 0.23 |
| Max force (µN) | 15.1 ± 4.6 | 12.6 ± 3.5a |
| Max tension (kN/m2) | 39.9 ± 3.4 | 34.9 ± 3.2a |
| ktr @ pCa 4.5 (s−1) | 0.712 ± 0.08 | 0.595 ± 0.06a |
| pCa for half-maximal force | 6.08 ± 0.03 | 5.88 ± 0.03a |
| Relative force (PO/P4.5) | 0.49 ± 0.04 | 0.55 ± 0.03 |
| a/PO | 0.16 ± 0.02 | 0.23 ± 0.05 |
| Fopt (P/PO) | 0.266 ± 0.01 | 0.291 ± 0.02 |
| Vopt (ML/s) | 0.104 ± 0.010 | 0.117 ± 0.013 |
| Vmax | 0.39 ± 0.04 | 0.42 ± 0.08 |
| PNPO (P/PO*ML/s) | 0.027 ± 0.002 | 0.033 ± 0.003a |
| Submax ktr | 0.552 ± 0.10 | 0.772 ± 0.11a |
Mechanical properties were tested before and after cTn exchange and compared via paired t test analysis. Values are mean ± SEM.
P ≤ 0.05. n equals the number of human hearts (biological replicates), with one cardiac myocyte preparation per heart.